Improving Immunotherapy Efficacy and Safety details the latest developments in immunotherapy, including established and emerging targets and modalities, new engineering strategies, combinations, biomarkers, effective preclinical models and strategies to mitigate toxicity and recent clinical developments. Cambridge Healthtech Institute’s 6th Improving Immunotherapy Efficacy and Safety conference focuses on the latest engineering strategies, targets and modalities being adopted to improve immunotherapy efficacy and safety. Topics include new and emerging targets, immune tolerance, the role of the tumor microenvironment, TRegs, plus effective strategies to mitigate toxicity. Examples will come from the world of checkpoint inhibitors, agonists, adoptive T cell therapy, combinations, and oncolytic viruses, amongst others. All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
1. Medical 2. Research 3. Biotech 4. Education 5. Conferences
At Cambridge Healthtech Institute (CHI), we believe bringing together a unique and diverse constellation of innovators, scientists, and life science professionals can hold the key to developing tomorrow’s cures and diagnostics.
